Daily weight-loss pill with low side effects advances toward US sale

A once-a-day, low-impact oral GLP-1 pill known as CX11 has passed its efficacy test on US patients to advance to the first North American Phase 3 trial. It's already cleared its first Phase 3 study in China.

Continue Reading

Category: Obesity, Illnesses and conditions, Body and Mind

Tags: GLP-1 receptor agonists, Weight Loss, clinical trials, Fat cells, peptide, Pharmaceuticals, BioLogic, Experimental, Obesity